Country: Malta
Language: English
Source: Medicines Authority
POLIOVIRUS, INACTIVATED, TYPE, MAHONEY STRAIN, MEF, SAUKETT STRAIN
Sanofi Pasteur 14 Espace Henry Vallée , 69007 Lyon, France
J07BF03
POLIOVIRUS (INACTIVATED) TYPE 1 (MAHONEY STRAIN) 40 DAgU POLIOVIRUS (INACTIVATED) TYPE 2 (MEF-1 STRAIN) 8 DAgU POLIOVIRUS (INACTIVATED) TYPE 3 (SAUKETT STRAIN) 32 DAgU
SUSPENSION FOR INJECTION
POLIOVIRUS (INACTIVATED) TYPE 1 (MAHONEY STRAIN) 40 DAgU POLIOVIRUS (INACTIVATED) TYPE 2 (MEF-1 STRAIN) 8 DAgU POLIOVIRUS (INACTIVATED) TYPE 3 (SAUKETT STRAIN) 32 DAgU
POM
VACCINES
Authorised
2007-02-13
PACKAGE LEAFLET: INFORMATION FOR THE USER NAME OF THE MEDICINAL PRODUCT IMOVAX POLIO, SUSPENSION FOR INJECTION IN PREFILLED SYRINGE POLIOMYELITIS VACCINE (INACTIVATED) BOXED TEXT READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD ARE VACCINATED, BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always use this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse has told you. • Keep this leaflet. You may need to read it again. • Ask your pharmacist if you need more information or advice. • If you or your child get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What IMOVAX POLIO, suspension for injection in prefilled syringe is and what it is used for 2. What you need to know before you use IMOVAX POLIO, suspension for injection in prefilled syringe 3. How to use IMOVAX POLIO, suspension for injection in prefilled syringe 4. Possible side effects 5. How to store IMOVAX POLIO, suspension for injection in prefilled syringe 6. Contents of the pack and other information 1. WHAT IMOVAX POLIO, SUSPENSION FOR INJECTION IN PREFILLED SYRINGE IS AND WHAT IT IS USED FOR PHARMACOTHERAPEUTIC GROUP: VACCINE AGAINST POLIOMYELITIS - ATC CODE: J07BF03 IMOVAX POLIO is a vaccine. Vaccines are used to protect against infectious diseases. When IMOVAX POLIO is injected, the body’s natural defences develop a protection against those diseases. This vaccine is indicated for the prevention of poliomyelitis in infants, children and adults, for primary vaccination (series of first vaccinations) and as a booster. IMOVAX POLIO must be used according to effective official recommendations. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE IMOVAX POLIO, SUSPENSION FOR INJECTION IN PREFILLED SYRINGE DO NOT USE IMOVAX POLIO, SUSPENSION FOR INJECTION IN PREFILLED SYRINGE IF YOU OR YOUR CHILD: • are allergic (hypersensitive) to the active substances or to any of the other components of IM Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT IMOVAX POLIO, SUSPENSION FOR INJECTION IN PREFILLED SYRINGE POLIOMYELITIS VACCINE (INACTIVATED) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 ml) contains: Poliomyelitis virus (inactivated) Type 1 (Mahoney strain)# ............................................................................................................ 29 D-antigen units* Type 2 (MEF-1 strain)# .................................................................................................................. 7 D-antigen units* Type 3 (Saukett strain)# ............................................................................................................... 26 D-antigen units* This vaccine complies with European Pharmacopoeia requirements and WHO recommendations. # Cultivated on VERO cells * These antigen quantities are strictly the same as those previously expressed as 40-8-32 D- antigen units, for virus type 1, 2 and 3 respectively, when measured by another suitable immunochemical method Excipients with known effect Phenylalanine……………12.5 micrograms Ethanol…………….…….2 milligrams (See section 4.4) IMOVAX POLIO may contain traces of neomycin, streptomycin and polymyxin B (see section 4.3). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Suspension for injection in prefilled syringe. IMOVAX POLIO is a clear and colourless suspension. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS This vaccine is indicated for the prevention of poliomyelitis in infants, children and adults, for primary and booster vaccination. IMOVAX POLIO must be used according to effective official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY _Paediatric population _ Dosage regimen compliant with French recommendations: • 2 injections at an interval of two months, one at the age of 2 months and one at the age of 4 months (primary vaccination) followed by a first booster at the age of 11 months. Other dosage regimens co Read the complete document